Moderna Aktie News

Moderna may look appealing right now, given the company's high cash balance and extensive drug pipeline. However, as Moderna's cash burn dilemma persists, the company's net value will likely keep declining.

"Buying the dip" can be a double-edged sword for investors. Sometimes they can seize the opportunity by purchasing an oversold stock, but other times, that stock is trending lower for a good reason (and just might stay there).

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows: Late-Breaking Oral Presentation #229: mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults A...

Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and Moderna continue to actively diversify their portfolios of experimental drugs and vaccines toward cancer treatment.

Moderna, Inc. (NASDAQ:MRNA ) Shareholder/Analyst Call October 17, 2025 12:00 PM EDT Company Participants Kyle Holen Lavina Talukdar - Senior VP & Head of Investor Relations Conference Call Participants Ryan Sullivan David Pinato Gregory Wiessner - TD Cowen, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Martial Descoutures - ODDO BHF Corporate & Markets, Resear...

CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update.

Can you believe that Moderna (MRNA 5.52%) was once worth more than $195 billion in 2021? Back then, the business looked on track to be the next big healthcare company.

Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. Moderna's cost-cutting measures and cash reserves provide a buffer, but lack of new product launches and market competition challenge near-term growth. Oncology pipeline, especially mRNA-4157 and mRNA-4359, offers long-term promise, but regulatory and re...